Financial News
All News about POLBF
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://public.newsdirect.com/684462050/Jrbh9rWl.jpg)
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Appointment of Joint Broker
April 29, 2024
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
March 19, 2024
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Director Share Purchase
February 19, 2024
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
December 11, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Directorate Change
November 30, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
November 21, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Former Amryt Pharma Leadership Team join Poolbeg
November 09, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
February 14, 2024
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
February 11, 2024
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
December 19, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
November 01, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Partners with a Nasdaq-Listed Biopharma
October 17, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
September 29, 2023
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
September 19, 2023
Via ACCESSWIRE
Poolbeg Pharma "moving forward rapidly" with POLB001
September 13, 2023
Via News Direct
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma "moving forward rapidly" with POLB001
September 13, 2023
Via TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.